UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript
Operator: Hello and welcome to UroGen Pharma First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Urogen Pharma Ltd. (URGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | SilverArc Capital Devesh Gandhi | 1,381,158 | $15,275,607 | +24% | 3.12% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 815,000 | $9,013,900 | -16% | 0.08% |
| 3. | Wildcat Capital Management Leonard A. Potter | 495,606 | $5,481,402 | 2.93% | |
| 4. | Hudson Bay Capital Management Sander Gerber | 410,607 | $4,541,313 | +76% | 0.01% |
| 5. | Stonepine Capital Timothy P. Lynch | 333,400 | $3,687,404 | +3% | 3.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.10 | 160 | Officer | 21,997 | 2021-11-18 | Filing | |
| $15.85 | 2,500 | Officer | 2,500 | 2021-05-17 | Filing | |
| $15.71 | 2,500 | Officer | 2,500 | 2021-05-17 | Filing | |
| $18.50 | 10,000 | Officer | 229,117 | 2020-12-14 | Filing | |
| $28.00 | 7,530 | Officer | 16,548 | 2019-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.14 | 1,896 | Officer | 148,540 | 2025-01-31 | Filing | |
| $11.14 | 1,896 | Officer | 147,103 | 2025-01-31 | Filing | |
| $11.14 | 759 | Officer | 145,666 | 2025-01-31 | Filing | |
| $11.14 | 2,767 | Officer | 32,514 | 2025-01-31 | Filing | |
| $11.14 | 3,354 | Officer | 29,781 | 2025-01-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,423,463 | $26,803,500 | 0% | |
| 2. | 2,303,031 | $25,471,523 | 0.17% | |
| 3. | 1,173,088 | $12,974,353 | 0% | |
| 4. | 473,330 | $5,235,029 | 0% | |
| 5. | 370,959 | $4,102,806 | 0% |
News See All
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the UroGen Pharma Fourth Quarter and Full Year 2024 Earnings Call.
10 Best Small-Cap Growth Stocks to Buy Now
On November 4, 2024, Nick Sheridan, Portfolio Manager at Janus Henderson released a report on small-cap stocks exploring how these stocks offer unique growth and diversification opportunities.
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by and welcome to the UroGen Pharma Third Quarter 2024 Earnings Call. Please be advised that today's conference is being recorded.
10 Worst Middle East and Africa Stocks To Buy According to Short Sellers
According to the IMF's Middle East and North Africa Economic Update from April 2024, the MENA region is expected to see moderate growth of 2.7% in 2024, up from 1.9% in 2023.
10 Worst ADR Stocks To Buy According to Short Sellers
An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company. These certificates allow U.S.
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the 2024 Second Quarter UroGen Pharma Earnings Call. [Operator Instructions] Please advise that today’s conference is being recorded.
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript
Operator: Good morning ladies and gentlemen. Thank you for standing by. Welcome to the UroGen Pharma First Quarter 2024 Earnings Call. Please be advised that today's conference is being recorded.
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Full Year 2023 Earnings Call. Please be advised that today's conference is being recorded.
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today's conference is being recorded.